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The successful development of safe and highly effective nanoprobes for targeted imaging and simultaneous therapy of
in vivo gastric cancer is a great challenge. Herein we reported for the first time that anti-α-subunit of ATP synthase
antibody, HAI-178 monoclonal antibody-conjugated fluorescent magnetic nanoparticles, was successfully used for
targeted imaging and simultaneous therapy of in vivo gastric cancer. A total of 172 specimens of gastric cancer tissues
were collected, and the expression of α-subunit of ATP synthase in gastric cancer tissues was investigated by
immunohistochemistry method. Fluorescent magnetic nanoparticles were prepared and conjugated with HAI-178
monoclonal antibody, and the resultant HAI-178 antibody-conjugated fluorescent magnetic nanoparticles (HAI-178-FMNPs)
were co-incubated with gastric cancer MGC803 cells and gastric mucous GES-1 cells. Gastric cancer-bearing nude mice
models were established, were injected with prepared HAI-178-FMNPs via tail vein, and were imaged by magnetic
resonance imaging and small animal fluorescent imaging system. The results showed that the α-subunit of ATP synthase
exhibited high expression in 94.7% of the gastric cancer tissues. The prepared HAI-178-FMNPs could target actively
MGC803 cells, realized fluorescent imaging and magnetic resonance imaging of in vivo gastric cancer, and actively
inhibited growth of gastric cancer cells. In conclusion, HAI-178 antibody-conjugated fluorescent magnetic nanoparticles
have a great potential in applications such as targeted imaging and simultaneous therapy of in vivo early gastric cancer
cells in the near future.
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Gastric cancer is the second most common cancer and
the third leading cause of cancer-related death in China
[1-3]. It remains very difficult to cure effectively, primarily
because most patients present with advanced diseases [4].
Therefore, how to recognize and track or kill early gastric
cancer cells is a great challenge for early diagnosis and
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in any medium, provided the original work is pWe have tried to establish an early gastric cancer pre-
warning and diagnosis system since 2005 [5,6]. We hoped
to find early gastric cancer cells in vivo by multi-mode tar-
geting imaging and serum biomarker detection techniques
[7-12]. Our previous studies showed that subcutaneous
and in situ gastric cancer tissues with 5 mm in diameter
could be recognized and treated by using multi-functional
nanoprobes such as BRCAA1-conjugated fluorescent
magnetic nanoparticles [13], her2 antibody-conjugated
RNase-A-associated CdTe quantum dots [14], folic acid-
conjugated upper conversion nanoparticles [15,16], RGD-
conjugated gold nanorods [17], ce6-conjugated carbon
dots [18], ce6-conjugated Au nanoclusters (Au NCs)
[19,20]. However, the clinical translation of these prepared
nanoprobes still exists as a great challenge because no one
kind of biomarker is specific for gastric cancer. Lookingn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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ment of safe and effective nanoprobes for targeted im-
aging and simultaneous therapy of in vivo early gastric
cancer have become our concerns.
Dr. Jian Ni et al. found that the α-subunit of ATP syn-
thase exhibited over-expression in breast cancer cell lines
such as MCF-7H and MCF-7 cell line, with different
metastasis potentials, and also exhibited high expression
in breast cancer tissues, hepatocellular carcinoma, colon
cancer, and prostate cancer [21]. ATP synthase is respon-
sible for ATP production in oxidative phosphorylation and
can work in reverse as a proton-pumping ATPase [22,23].
ATP synthase expression is localized exclusively in the
mitochondria where it generates most cellular ATP. How-
ever, ATP synthase components have recently been identi-
fied as cell-surface receptors for apparently unrelated
ligands in the course of studies carried out on angiogenesis
[24-26], lipoprotein metabolism [27], innate immunity
[28-32], etc. by immunofluorescence, biochemistry, and
proteomics analyses. Its molecular mechanism, function,
and significance have not been clarified well.
Dr. Jian Ni's group prepared specific monoclonal anti-
body against the α-subunit of ATP synthase, named as
HAI-178 antibody, and provided this to my group. Our pri-
mary studies showed that the α-subunit of ATP synthase
also exhibited over-expression in gastric cancer cells and
clinical gastric cancer tissues, with no or very low expres-
sion in normal gastric mucous tissues. Especially as one
kind of self antibody which existed in human sera from
patients with gastric cancer, this should be a potential
biomarker with diagnosis value. In our previous work, we
prepared fluorescent magnetic nanoparticles (FMNPs)
composed of silicon-wrapped magnetic nanoparticles and
CdTe quantum dots and used FMNPs-labeled MSC cells to
realize the targeted imaging and hyperthermia therapy of
in vivo gastric cancer [33]. We also confirmed that the
prepared fluorescent magnetic nanoparticles show good
biocompatibility [34].
In the present study, we fully used the advantages of
FMNPs and potential gastric cancer biomarker α-
subunit of ATP synthase, prepared HAI-178 monoclonal
antibody-conjugated FMNPs, and investigated the feasibil-
ity of prepared nanoprobes to target in vitro and in vivo
gastric cancer cells. Our results show that as-prepared
nanoprobes can be used for in vivo dual-model imaging
and therapy of in vivo cancer, and have great potential in
applications such as dual-model imaging and simultan-
eous therapy of early gastric cancer in the near future.Methods
All animal experiments (no. SYXK2007-0025) were
approved by the Institutional Animal Care and Use
Committee of Shanghai Jiao Tong University.Expression of α-subunit of ATP synthase in gastric
cancer tissues
HAI-178 monoclonal antibody was presented as a gift by
Dr. Jian Ni. HAI-178 monoclonal antibody was used as
first antibody to stain 172 specimens of gastric cancer
and control gastric mucous tissues with immunohisto-
chemistry method [35], which were collected from Xi’an
Central Hospital, Xianya Hospital, Changzheng Hospital,
and the First People's Hospital in Shanghai, and identi-
fied by pathological examination.Preparation and Surface functionalization of FMNPs
FMNPs were prepared according to our previous report
[36-38]. Before coupling the FMNPs with the HAI-178
antibody, we first functionalized the surface functional
group of FMNPs as carboxyl group. Solutions of 95 mL
ethanol and 2 mL 3-aminopropyltriethoxysilane (APS)
were added to form a mixed solution and allowed to
react at room temperature for 24 h. The aminosilane-
modified FMNPs were separated by permanent magnet
and were washed with deionized water three times then
redispersed the FMNPs-NH2 in 100 mL dimethylforma-
mide (DMF) and added with excess succinic anhydride
to form a mixed solution and react at room temperature
for 24 h. The carboxyl-modified FMNPs were separated
by permanent magnet again and washed with deionized
water three times.Preparation and characterization of HAI-178 monoclonal
antibody-conjugated FMNPs
We used a two-step process to obtain stable HAI-178-
antibody-FMNPs conjugation. Solution of 1.5 mg FMNPs-
COOH was dispersed in 2 mL pH 7 PBS buffer and was
sonicated for 10 min. Then we mixed 1 mL of fresh 400
mM EDC and 100 mM NHSS in pH 6.0 MES buffer and
rotated it at room temperature for 15 min. After this, the
resulting solution was separated by magnetic field, and 1
mg/mL of HAI-178 monoclonal antibody was added to
the above mixture and stirred in dark place for 2 h. To
remove free HAI-178 antibody, the residual reaction
mixture was separated by magnetic field and the solid
remaining was washed with 1 mL of PBS buffer three
times. Finally, 1 mL of 0.05% Tween-20/PBS was added to
the HAI-178 antibody-FMNPs conjugation and the bio-
conjugation was stored at 4°C. When used, this HAI-178
antibody-FMNPs conjugation should be diluted with PBS/
0.05% Tween-20. Then we used the Nano Drop device to
quantify the coupling rate of HAI-178 antibody with
FMNPs-COOH. Before the coupling reaction, we mea-
sured the total concentration of HAI-178 antibody. After
the coupling reaction, we measured the HAI-178 antibody
concentration in residual reaction mixture and calculated
the coupling rate according the equation:
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in residual reaction mixture/Total concentration of HAI-
178 antibody) × 100. The as-prepared nanoprobes and
pure FMNPs were characterized by transmission electron
microscopy, photoluminescence (PL) spectrometry, and
fluorescent microscopy.Nanoprobes for in vitro targeting imaging of gastric
cancer cells
Gastric cancer cell line MGC803 cells with over-expression
of α-subunit of ATP synthase were used as target cells, and
human gastric mucous GES-1 cells without expression of
α-subunit of ATP synthase was used as control. The cells
were cultured and collected, then were treated with 50 μg/
mL HAI-178 antibody-conjugated FMNPs nanoprobes,
and cultured in a humidified 5% CO2-balanced air incuba-
tor at 37°C for 4 h. Meanwhile, the MGC803 and GES-1
cells were treated with FMNPs as the control group. After-
ward, the cells were rinsed with PBS three times, and then
the cells were fixed with 2.5% glutaraldehyde solution for
30 min. For nuclear counterstaining, MGC803 cells were
incubated with 1 mM Hoechst 33258 (Invitrogen, Life
Technologies, Carlsbad, CA, USA) in PBS for 5 min. The
cells were observed and imaged using fluorescence micro-
scope (Nikon TS100-F, Nikon Instruments, Shanghai,
China).Nanoprobes for fluorescence imaging of gastric
cancer-bearing nude mice
Animal experiments were performed according to Guide-
lines for Animal Care and Use Committee, Shanghai Jiao
Tong University. Male athymic nude mice were obtained
from Shanghai LAC Laboratory Animal Co. Ltd., Chinese
Academy of Sciences (Shanghai, China). MGC803 cells
(1 × 106) were injected subcutaneously into the right an-
terior flank area of the male nude mice with 4 to 5 weeks
of age. The tumors were allowed to grow to a diameter of
approximately 5 mm. At that point, about 40 μg HAI-178
antibody-FMNPs nanoprobes was injected into the mice
(n = 3) via the tail vein. Mice were respectively monitored
in a non-invasive manner at 0.5, 1, 3, 6, and 12 h to get
fluorescence images. Then, tumor and major organs were
collected, were placed on black papers, and subjected to
IVIS Lumina imaging system (Xenogen) with emission
wavelengths of 630 nm. The fluorescence images were ac-
quired, and the total fluorescence flux for each sample
was obtained. For the control experiment, mice (n = 3)
were injected via tail vein with 40 μg of FMNPs and
subjected to optical imaging at various time points
post-injection. Identical illumination settings (e.g., lamp
voltage, filter, exposure time) were used in all animal
imaging experiments.Nanoprobes for MRI and fluorescent imaging of gastric
cancer-bearing nude mice
For MR imaging, gastric MGC803 cells (1 × 106) were
injected subcutaneously into the right anterior flank area
of male nude mice (n = 3) with 4 to 5 weeks of age. After
the tumors reached approximately 5 mm in diameter,
mice were injected with the HAI-178 antibody-FMNPs
nanoprobes. MR imaging was performed at 6 h post-
injections on animals anesthetized with 0.4% pentobar-
bital, using 3.0 T field intensity by GE HDX 3.0 T MR
imaging instrument (GE Healthcare, Beijing, China)
equipped with GE Signal Excite 3.0 T magnetic reson-
ance imaging (MRI) software. The imaging protocol
consisted of coronal and transverse T2-weighted spin
echo (SE) pulse sequences. To produce T2 maps, the
following imaging parameters were used: TR/TE =
1,000/10, 20, 30, 40, 40, 50, 60, 70, 80 ms; FOV = 8.0
cm; NEX = 1; slice thickness = 2.0 mm; number of excita-
tions = 2. MR imaging was performed on the mice (n = 3)
model with gastric tumor, and injected FMNPs without
labeling HAI-178 antibody were used for the negative
control. Then, the mice models with gastric cancer
were injected with 40 μg HAI-178–FMNPs via the tail
vein and imaged by small animal imaging system at 6 h
post-injection [13].Nanoprobes for integrated therapy of in vivo gastric
cancer
Gastric cancer-bearing mice were randomly divided into
four groups: test group 1 (10 mice) (200 μg of HAI-178-
FMNPs plus external alternating magnetic field with 63
kHz and 7 kA/m for 4 min), test group 2 (10 mice) (200
μg of FMNPs plus external alternating magnetic field with
63 kHz and 7 kA/m for 4 min), test group 3 (10 mice)
(100 μg of HAI-178 antibody), and blank control (5 mice)
(saline). Every 2 days, the mice sizes were measured up to
14 days, then the mice were sacrificed.Effects of HAI-178-FMNPs on important organs
The mice in test group were sacrificed after in vivo im-
aging. For histological evaluation, excised important organs
from the heart, liver, spleen, lung, and kidney were frozen
and embedded by medium at −20°C, were sectioned into
8-μm slices, were stained by hematoxylin and eosin (HE)
stain method, and were observed by microscopy.Statistical analysis
Each experiment was repeated three times in duplicate.
The results were presented as mean ± SD. Statistical
differences were evaluated using the t-test and considered
significance at P < 0.05.
Figure 1 Expression of α-subunit of ATP synthase in gastric cancer tissues and gastric mucous tissues (×50). (A) Positive expression in
gastric cancer tissues. (B) Negative expression in normal gastric mucous tissues.
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Expression of α-subunit of ATP synthase in gastric
cancer tissues
Figure 1A showed the positive expression of α-subunit of
ATP synthase in gastric cancer tissues; Figure 1B showed
the negative expression of α-subunit of ATP synthase in
gastric mucous tissues. We investigated the expression of
α-subunit of ATP synthase in 172 specimens of gastric
cancer tissues by immunohistochemistry method. As
shown in Table 1, α-subunit of ATP synthase exhibited
over-expression in 94.7% of the gastric cancer tissues. In
no or very low expression in normal gastric mucous
tissues, there existed a statistical difference between two
groups (P < 0.01). We also observed that the expression
of α-subunit of ATP synthase is not associated with
patient's age (P > 0.05) and positive lymph node and inva-
sion (P > 0.05). However, it is positively associated with
the size of tumor (P < 0.05), pathological grade (P < 0.05),
and TNM stage (P < 0.05). This result highly suggests that
α-subunit of ATP synthase may be a potential biomarker
for most gastric cancer patients and may be veryTable 1 Clinicopathological data and ATP synthase α-subunit
Description α-ATP synt
Negative Mo
Age <50 5 (6.8%) 31
≥50 4 (4.0%) 32
Size <2 cm 2 (11.7%) 11
≥2 cm 2 (3.4%) 22
Histological grade Well 3 (11.5%) 12
Moderate 7 (6.0%) 43
Poor 0 (0.0%) 3
TNM stage I 2 (18.1%) 5
II 2 (4.3%) 25
III 0 (0%) 3
Lymph node invasion Positive 3 (5.6%) 19
Negative 2 (4.5%) 13valuable for diagnosis and therapy of clinical gastric
cancer patients.Preparation and characterization of HAI-178-FMNPs
nanoprobes
As shown in Figure 2A, prepared FMNPs were composed
of silica-wrapped CdTe and magnetic nanoparticles, and
their sizes were 50 nm or so in diameter. As shown in
Figure 2B, after FMNPs were conjugated with HAI-178
antibody, the as-prepared nanoprobes' photoluminescence
(PL) intensity was lower than that of FMNPs, exhibiting a
left shift of 40 nm, which was due to the decrease in the
polarization rate of the surrounding molecules, resulting
in the decrease of stokes displacement and finally resulting
in a blue shift in the emission spectra. Figure 2C showed
that prepared FMNPs exhibited green color. Figure 2D
showed that the magnesium intensity of as-prepared
FMNPs and magnetic nanoparticles was 3.21 emu/g.
In the course of preparing HAI-178 antibody-FMNPs
nanoprobes, we found that the surface functionalizationexpression in 172 gastric cancers
hase expression Total P value
derate Strong
(42.4%) 37 (50.6%) 73 (100%) Not significant
(32.3%) 63 (63.6%) 99 (100%)
(64.7%) 4 (23.5%) 17 (100%) P < 0.05
(37.9%) 31 (53.4%) 58 (100%)
(46.1%) 11 (42.3%) 26 (100%) P < 0.05
(37.0%) 66 (56.8%) 116 (100%)
(15.0%) 17 (85.0%) 20 (100%)
(45.4%) 4 (36.3%) 11 (100%) P < 0.05
(54.3%) 19 (41.3%) 46 (100%)
(23.1) 10 (76.9%) 13 (100%)
(35.8) 31 (58.4) 53 (100%) Not significant
(29.5%) 31 (70.4%) 44 (100%)
Figure 2 Characterization of FMNPs and HAI-178-FMNPs. (A) HR-TEM of FMNPs. (B) PL spectra of FMNPs and HAI-178-FMNPs. (C) Fluorescent
image of prepared FMNPs. (D) Magnesium of FMNPs and magnetic nanoparticles
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body with FMNPs via covalent bond. We observed that
carboxyl groups on the surface of FMNPs conjugated
with HAI-178 antibody easier than amino groups on
the surface of FMNPs. In our experiment, the average
coupling rate of HAI-178 antibody with FMNPs-
COOH was 80.29%.
Nanoprobes for targeting in vitro gastric cancer cells
The targeting ability of as-prepared nanoprobes in vitro was
observed by fluorescence microscope. As shown in
Figure 3A, HAI-178-conjugated FMNPs existed around
MGC803 cellular membrane. HAI-178 antibody-FMNPs
nanoprobes could enter into the cytoplasm of MGC803
cells after 4 h incubation with MGC803 cells, but not inside
the nucleus, which highly suggests that HAI-178 antibody-
conjugated FMNPs can target MGC803 cells specifically.Figure 3 Fluorescent microscope observation of HAI-178-FMNPs boun
surface of MGC803 cell membrane (×10); inset is the magnified image (×10
nucleus (DAPI staining) (×10).Nanoprobes for fluorescent imaging of in vivo gastric
cancer cells
To evaluate the tumor-targeting properties of HAI-178
antibody-conjugated FMNPs nanoprobes, MGC803 cells-
bearing nude mice models were prepared and monitored
under a non-invasive manner for 12 h by using IVIS fluores-
cence imaging system. Figure 4A showed the nude mouse
loaded with MGC803 gastric cancer cells. Figure 4B
showed the strong fluorescent signal in the tumor site of
gastric cancer-bearing nude mouse at 12 h post-injection.
Figure 4C showed that strong fluorescent signals only
existed in the tumor site of gastric cancer-bearing nude
mouse. These results indicated that the HAI-178
antibody-conjugated FMNPs were preferentially accumu-
lated in the tumor tissues and highly suggest that prepared
nanoprobes can target efficiently tumor tissues inside gas-
tric cancer-bearing nude mice.d to surface of MGC803 cells. (A) HAI-178-FMNPs combined to the
0). (B) HAI-178-FMNPs bound to the membrane of MGC803 cells, blue
Figure 4 Fluorescent imaging of gastric cancer-bearing nude
mouse via tail vein injection with HAI-178-FMNPs by animal
imaging system. (A) Nude mouse loaded with gastric cancer.
(B) Fluorescent imaging of the tumor site. (C) Overlay picture of gastric
cancer-bearing nude mouse and fluorescent imaging of the tumor site.
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nude mice
In vivo MR imaging was performed on nude mice loaded
with subcutaneous gastric cancer at 12 h post-injection.
Representative images of T2 maps were shown in
Figure 5. Figure 5A showed MR image of the nude
mouse loaded with gastric cancer at longitudinal section,
with circle showing the tumor site; a significant change
in signal intensity was observed in site of tumor, indicat-
ing that there existed accumulation of the nanoprobes in
the tumor site as shown in Figure 5B, showing the MR
image of nude mouse at transverse direction. Our result
showed that prepared nanoprobes can be used for tar-
geted MR imaging of in vivo gastric cancer.Figure 5 MRI image of gastric cancer-bearing nude mouse. (A) MRI im
(B) MRI image of nude mice at horizontal direction; circle shows the tumoNanoprobes for therapy of gastric cancer-bearing
nude mice
As shown in Figure 6, the tumor tissues in control group
(treated with saline) grew very quick, and the relative tumor
volume became bigger and bigger as the feeding day in-
creased. In the test group treated with FMNPs, under exter-
nal alternating magnetic field with 63 kHz and 7 kA/m for 4
min, the tumor tissues in gastric cancer-bearing mice grew
slower than the mice in control group. In the test group
treated with HAI-178 antibody, the tumor tissues grew
slower, which highly showed that HAI-178 could inhibit the
growth of gastric cancer in vivo, similar to the inhibition of
growth of breast cancer in vivo [26]. In test group HAI-178-
FMNPs, the tumor tissues grew slowest, which highly indi-
cate that the prepared HAI-178-FMNPs have a therapeutic
function for gastric cancer in vivo. Compared with the
control group, a statistical difference existed between two
groups (P < 0.05). Our results showed that the prepared
HAI-178-conjugated FMNPs have a therapeutic function.
Pathological analysis of important organs
As shown in Figure 7, we used HE staining to check im-
portant organs including the heart, liver, spleen, lung and
kidney, and no obvious damages were observed, which
indirectly suggest that the prepared HAI-178-FMNPs
nanoprobes did not damage important organs, showing
good biocompatibility.
Potential mechanism of targeting imaging and therapy of
gastric cancer
In recent years, with the development of ‘omics,’ systems
biology, and molecular imaging, a tendency of integration
of multi-modality, multi-target imaging, and theranosticage of nude mouse at longitudinal direction; circle shows tumor site.
r site.
Figure 6 Relative tumor volume of nude mice under different
treated condition.
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‘systems molecular imaging’ was suggested by Dr. Shen,
which can be used to show the complexity, diversity, and
in vivo biological behavior and the development and pro-
gress of disease in an organism qualitatively and quantita-
tively at a systems level. Ultimately, system molecular
imaging should enable the physicians not only to diagnose
tumors accurately but also to provide ‘on the spot’ treat-
ment efficiently. It will become comprehensive research
tools and technical means [39-44].
In this study, with the aim of integrating multi-mode tar-
geted imaging and simultaneous therapy into a nanoprobe,
we prepared HAI-178 antibody-conjugated FMNPs. Our
previous work showed that FMNPs are very stable and
have strong fluorescent signals and magnetic intensity, as
well good biocompatibility. Using the strong fluorescent
signals of the as-prepared nanoprobes, we successfully
obtained the targeted fluorescent images of in vivo gastric
cancer tissues in tumor-bearing nude mice, and using the
strong magnetic signals of the as-prepared nanoprobes, we
also successfully obtained MR images of in vivo gastric
cancer tissues in tumor-bearing nude mice. It is confirmedFigure 7 HE staining of important organs such as the heart, liver, splethat HAI-178 antibody can inhibit the growth of breast
cancer cells [21]; up to date, no report is closely associated
with HAI-178 antibody to inhibit growth of gastric cancer.
Our results confirmed for the first time that HAI-178 anti-
body could be used for therapy of in vivo gastric cancer.
How to target in vivo gastric cancer cells is a key scien-
tific problem [45]. Up to date, no specific gastric cancer
biomarkers were reported. Dr. Ni et al. found that α-
subunit of ATP synthase exhibited over-expression in
breast cancer tissues. In our study, we confirmed that α-
subunit of ATP synthase also exhibited over-expression in
94.7% of the gastric cancer specimens, which highly indi-
cate that the α-subunit of ATP synthase may be a poten-
tial target for gastric cancer diagnosis and therapy. We
also observed that the α-subunit of ATP synthase exhib-
ited over-expression in MGC803 cells, and we used anti-
α-subunit of ATP synthase antibody, that is, HAI-178
monoclonal antibody, to conjugate with florescent mag-
netic nanoparticles. The resultant HAI-178 antibody-
conjugated FMNPs successfully realized targeted imaging
and simultaneous therapy of in vivo gastric cancer, which
highly suggests that HAI-178 antibody can target,
recognize, and kill in vivo cancer cells, specially gastric
cancer cells. Thus, the prepared nanoprobes have a great
potential in applications such as targeted dual model im-
aging and selective therapy of early gastric cancer.
Conclusions
We successfully prepared novel HAI-178 antibody-
conjugated FMNPs nanoprobes which can be used for tar-
geted two modal imaging of gastric cancer and have an
obviously specific targeting ability toward gastric cancer
tissues at 2 h of post-injection. In addition, HAI-178
antibody-conjugated FMNPs nanoprobes also exhibited
inhibition of growth of gastric cancer, as first reported in
this study. The as-prepared nanoprobes also can be used
for hyperthermia therapy of gastric cancer under in vitro
alternating magnetic field irradiation and have great
potential in applications such as simultaneous targeted
imaging and targeting therapy of clinical gastric cancer in
the near future.en, kidney, and lung.
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